Skip to content
NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP

IGC Pharma, Inc. IGC

15 fiscal years on record · USD · FY2024 reported · SEC filings only
$1.3M
▼ 5.5% YoY
$-7.1M
$-4.9M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 1.3M
Revenue, FY2024 · full 15-year series below
Revenue $M Net income $M
FY2024 · Revenue 1.3 · Net income -7.1
3M6M-10M-20M
201020132016201920222024
Compound annual growth
+47.4%
−20.8%
−16.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −20.8% a year over the five years to FY2024.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−560 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -585.8% · Net -560.3%
-1000%-2000%-3000%
201020172024
ROE
FY2024 · ROE -104.3%
-50%-100%
201020172024
Three returns, three denominators.

Each USD of equity lost 104 cents this year.

Cash & shareholders

·
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -4.9
-5M-10M
201020172024

Total assetsUSD 8.7M
EquityUSD 6.3M
CashUSD 405,000.00
Gross debtUSD 137,000.00
Net debtUSD -268,000.00
Current ratio1.28×

The company holds more cash than debt.

The 15-year record

15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
IGC, 15-year financial record
Metric 202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.00.00.00.00.00.00.0−0.00.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0
EPS, diluted $−0.09−0.22◌◌−0.21−0.19−0.13−0.06−0.07−0.17−0.31−0.37−0.32−2.66−1.34
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————
ROE %−104.3−116.9−59.3−53.0−29.7−24.3−19.7−23.2−17.9−20.3−33.1−21.5−15.4−72.1−123.3
Shares out B0.080.070.050.050.050.040.040.030.030.020.010.010.010.060.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 68 reconciliationsAUDITED

Reconciled in 15 of the 15 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: EPS is not tagged before 2010. Three checks were skipped: revenue is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inMaryland
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image